mutation class

Small Mutation

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

191 sites for NCT04821622

ATM Loss, +27 more biomarkers

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

315 sites for NCT04497844

ATM Loss, +61 more biomarkers

Prostate Adenocarcinoma

abiraterone, +2 more drugs

hormone therapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

53 sites for NCT04915755

BRCA1 Loss, +8 more biomarkers

Breast Carcinoma

niraparib

targeted therapy

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

253 sites for NCT04739800

BRCA1 Mutation, +1 more biomarker

Fallopian Tube Clear Cell Adenocarcinoma, +20 more conditions

cediranib, +2 more drugs

immunotherapy, +1 more type

olaparib

BRCA1 Loss, +3 more biomarkers

Breast Carcinoma

Early stage, +1 more state

Adjuvant

olaparib

targeted therapy

olaparib

ATM Loss, +27 more biomarkers

Prostate Carcinoma

Castration-resistant, +1 more state

Subsequent line

olaparib

targeted therapy

rucaparib

BRCA1 Loss, +3 more biomarkers

Prostate Carcinoma

Castration-resistant, +1 more state

Subsequent line

rucaparib

targeted therapy

bevacizumab + olaparib

BRCA1 Loss, +4 more biomarkers

Fallopian Tube Carcinoma, +2 more conditions

Advanced

Maintenance

bevacizumab, +1 more drug

targeted therapy

olaparib

BRCA1 Loss, +3 more biomarkers

Pancreatic Adenocarcinoma

Metastatic

Maintenance

olaparib

targeted therapy

niraparib

BRCA1 Loss, +4 more biomarkers

Fallopian Tube Carcinoma, +2 more conditions

Advanced

Subsequent line

niraparib

targeted therapy